Who are TachoSil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Usage of Fibrin sealant, Fibrin Sealant (FS) Grifols, Fibrin Sealant VH S/D, Fibrin sealant (FS2), Fibrin sealant hemipelvis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tachosil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TachoSil — Competitive Intelligence Brief

TachoSil (TachoSil) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agent / Fibrin sealant. Area: Surgery / Hemostasis.

marketed Hemostatic agent / Fibrin sealant Fibrinogen (conversion to fibrin via thrombin) Surgery / Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

TachoSil (TachoSil) — GATT Technologies BV. TachoSil is a hemostatic agent that combines fibrin glue with collagen to promote rapid blood clotting and wound sealing.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TachoSil TARGET	TachoSil	GATT Technologies BV	marketed	Hemostatic agent / Fibrin sealant	Fibrinogen (conversion to fibrin via thrombin)
Usage of Fibrin sealant	Usage of Fibrin sealant	Samsung Medical Center	phase 3	Hemostatic agent / Fibrin sealant	Fibrinogen / Factor XIII
Fibrin Sealant (FS) Grifols	Fibrin Sealant (FS) Grifols	Grifols Biologicals, LLC	phase 3	Hemostatic agent / Fibrin sealant	Fibrinogen (substrate for thrombin-mediated polymerization)
Fibrin Sealant VH S/D	Fibrin Sealant VH S/D	Baxter Healthcare Corporation	phase 3	Hemostatic agent / Fibrin sealant	Fibrinogen (substrate); thrombin (enzyme)
Fibrin sealant (FS2)	Fibrin sealant (FS2)	Ethicon, Inc.	phase 3	Hemostatic agent / Fibrin sealant
Fibrin sealant hemipelvis	Fibrin sealant hemipelvis	IBON JAUNARENA	phase 3	Hemostatic agent / Fibrin sealant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemostatic agent / Fibrin sealant class)

Baxter Healthcare Corporation · 1 drug in this class
Ethicon, Inc. · 1 drug in this class
GATT Technologies BV · 1 drug in this class
Grifols Biologicals, LLC · 1 drug in this class
IBON JAUNARENA · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TachoSil — Competitive Intelligence Brief. https://druglandscape.com/ci/tachosil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab